Appeals Court Affirms Dismissal of Privacy Lawsuit Involving 340B Contract Pharmacy

A federal appeals court affirmed the legality of Walgreens' handling of customers' personal identifying information for 340B purposes.

A federal appeals court has affirmed a lower court’s dismissal of a lawsuit alleging that Walgreens’ internal transfer of pharmacy customers’ personal identifying information (PII) for 340B drug discount drug purposes violates South Carolina and federal privacy laws.

The U.S.

Read More »

BMS Tells 340B Entities It Has Lifted Purchasing Limits on Leukemia Drug

BMS's Celgene subsidiary has lifted purchasing limits for 340B covered entities and non-340B buyers on its injectable acute myeloid leukemia (AML) drug Vidaza.

Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.

BMS announced the switch back to normal sales in

Read More »

During Crucial Oral Arguments in AstraZeneca 340B Suit, Feds Urge Judge to Take a Fresh Look at Their Case

A federal district judge in Delaware heard arguments yesterday in AstraZeneca's 340B contract pharmacy lawsuit against the government.

A federal government lawyer told a judge during a hearing yesterday that the government’s case against AstraZeneca and other drug companies that deny 340B drug discounts when covered entities use contract pharmacies is “in a very different posture” than it

Read More »

Arkansas Ending PhRMA Proceeding Against State 340B Contract Pharmacy Law as Focus Turns to Federal Lawsuit

Arkansas's insurance commissioner is ending PhRMA's state administrative proceeding to stop his department from implementing and enforcing the state’s 340B contract pharmacy law.

The Arkansas Insurance Department (AID) is ending the drug industry’s state administrative proceeding to stop the department from implementing and enforcing the state’s novel 340B contract pharmacy law.

In his Oct. 5 order ending the proceeding, Insurance Commissioner Alan

Read More »

340B ADR Rule Is Fundamentally Defective, PhRMA Tells Federal Court

PhRMA told a federal court in Baltimore, Md., that none of the federal government's legal arguments "can hide the fundamental defects" in the 340B ADR rule.

Pharmaceutical Research and Manufacturers of America told a federal district judge last week that the federal government has failed to refute PhRMA’s contention that the regulation establishing the 340B administrative dispute resolution (ADR) process “is unconstitutional, procedurally defective, and relies

Read More »

University White Paper on 340B Says Pharma and Hospitals Will Keep Testing 340B’s Bounds Until Congress Acts

Pharma and hospitals will keep testing the bounds of the 340B program until Congress steps in, a University of Southern California (USC) health policy research fellow predicts in a new white paper.

Drug manufacturers and hospitals “will likely continue to test the bounds” of the 340B program until Congress passes legislation addressing multiple concerns about it, a University of Southern California (USC) health policy research fellow says in a new white paper.

Read More »

Becerra Extends COVID-19 Public Health Emergency Through Mid-January

The COVID-19 national public health emergency (PHE) has been extended for a seventh time, to Jan. 13, 2022.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra on Friday extended the COVID-19 national public health emergency (PHE) for a seventh 90-day period.

Becerra’s Oct. 15 declaration means the PHE will last until Jan. 13, 2022, unless terminated

Read More »

News Alert: Judge Denies Sanofi Stay Against 340B ADR Proceedings, as Stakeholders Brace for Coming Whirlwind of Crucial Decisions in 340B Cases

A federal district judge yesterday denied Sanofi's emergency request for a stay against 340B ADR proceedings, in part because she said she will rule in Sanofi's 340B contract pharmacy lawsuit on or before Nov. 5.

A federal district judge in New Jersey has denied drug manufacturer Sanofi’s emergency motion for a stay against 340B administrative dispute resolution (ADR) proceedings—in part because she said she will hand down her decision in Sanofi’s 340B contract pharmacy lawsuit

Read More »

In Important Development, HHS Close to Rescinding Trump-era Rule that Undercuts its Sub-Regulatory Power

HHS is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including for 340B.

The U.S. Health and Human Services Department (HHS) is poised to rescind Trump administration regulations that have added to doubt about the authority of HHS guidance documents, including those for the 340B program.

During the Trump administration, the U.S Health

Read More »

A Closer Look at Critical Court Hearing on 340B Contract Pharmacy Legality

A federal district court in Washington, D.C., heard arguments this week in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

U.S. District Judge Dabney Friedrich all but told the federal government during a court hearing in Washington, D.C., on Tuesday she rejects its basic argument that the plain text of the 340B statute requires drug manufacturers to honor 340B purchases

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live